Showing 1 to 1 of 1 results
smh.com.au
🌐 85% Global Worthiness


NeuroScientific Bolsters Leadership Team for StemSmart Commercialization
NeuroScientific Biopharmaceuticals appointed Nathan Smith as CEO and Catherine Cole as chief medical officer, bolstering its team as it prepares for the commercial launch of its StemSmart stem cell technology, acquired through a $4.1 million purchase of Isopgen in June, which treats critically ill p...
NeuroScientific Bolsters Leadership Team for StemSmart Commercialization
NeuroScientific Biopharmaceuticals appointed Nathan Smith as CEO and Catherine Cole as chief medical officer, bolstering its team as it prepares for the commercial launch of its StemSmart stem cell technology, acquired through a $4.1 million purchase of Isopgen in June, which treats critically ill p...
Progress
40% Bias Score
Good Health and Well-being
Showing 1 to 1 of 1 results